Dr. Emerson Y. Chen, MD
Hematology & Oncology (Hematology & Oncology Physician)
3181 Sw Sam Jackson Park Rd, Mail Code: Oc14ho
Portland, OR 97239
- Medicare participating
At a glance
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 103
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
OR license MD182080
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohsu Hospital and Clinics Portland, OR
Medical groups
- University Professional Services (1,724 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 103
- Services billed
- 602
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 148 | 48 |
| Established patient office or other outpatient visit, 30-39 minutes | 64 | 37 |
| New patient office or other outpatient visit, 60-74 minutes | 26 | 26 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Dexamethasone Other prescribers in Portland, OR | 66 |
| Prochlorperazine Maleate Other prescribers in Portland, OR | 57 |
| Ondansetron Odt (ondansetron) Other prescribers in Portland, OR | 36 |
| Loperamide (loperamide hcl) Other prescribers in Portland, OR | 28 |
| Creon (lipase/protease/amylase) Other prescribers in Portland, OR | 25 |
| Pantoprazole Sodium Other prescribers in Portland, OR | 24 |
| Omeprazole Other prescribers in Portland, OR | 24 |
| Ursodiol Other prescribers in Portland, OR | 22 |
| Eliquis (apixaban) Other prescribers in Portland, OR | 17 |
| Ondansetron Hcl Other prescribers in Portland, OR | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $37.53 in total to this clinician.
| Janssen Research & Development, LLC | $37.53 |
|---|
| Food and Beverage | $37.53 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $478,965 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab MK-3475 Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy KEYNOTE 975
Merck Sharp & Dohme LLC - A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastat…
Janssen Research & Development, LLC - A Study of DS-1471a In Subjects With Advanced Solid Tumors
Daiichi Sankyo Inc. · Terminated · NCT06074705 - A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician s Choice in 3L Advanced,Metastatic Gastroesophageal Adenocarcinoma Gastric Adenocarcinom…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.